HIV
European Commission approves HIV prevention injection
August 28, 2025Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …
HIV vaccine candidate successfully optimised for industrial production
October 30, 2024Research and Development HIV, HIV/AIDS, Naobios, Sumagen, Vaccine, agreement
Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered with CDMO Naobios to industrialise …
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
July 23, 2024Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
Gilead shares phase 3 results from HIV prevention trial
June 21, 2024Research and Development Gilead, HIV, Infections and infestations, clinical trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …
Gilead and Merck share data from phase 2 trial of HIV treatment
March 7, 2024Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
February 21, 2024Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
October 26, 2023Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …
ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention
July 24, 2023Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …
FDA relaxes blood donation regulations for MSM
May 12, 2023Medical Communications FDA, HIV, HIV/AIDS, blood donation
The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …
GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs
June 22, 2021Manufacturing and Production GSK, HIV, ViiV Healthcare
ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …
New HIV prevention drug application submitted to FDA
May 5, 2021Research and Development FDA, HIV
ViiV Healthcare have initiated a rolling submission of a new drug application (NDA) with the FDA for their long-acting HIV …
Gilead and MSD partner to develop and commercialise two-drug HIV regimen
March 16, 2021Manufacturing and Production Gilead, HIV, MSD
Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …
ViiV presents positive long-term data for combined HIV treatment
March 8, 2021Sales and Marketing HIV, ViiV Healthcare
ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …
ViiV’s HIV drug Rukobia gets EC marketing authorisation
February 9, 2021Manufacturing and Production HIV, ViiV
The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …
Scripps Research and IAVI report positive findings from HIV vaccine Phase I trial
February 4, 2021HIV
Scripps Research and IAVI have returned positive Phase I results in their hunt for a HIV vaccine, detecting a targeted …
Latest content
